Mayes Patrick A sold $5.7M of INCY
Mayes Patrick A (EVP & Chief Scientific Officer) sold 47,954 shares of INCYTE CORP (INCY) at an average of $119.58 ($119.38–$122.19, $5.73M total) across 12 trades over 2026-07-31 to 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size, price range ($119.38 to $122.19), and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider selling activity, but the 10b5-1 framing reduces the likelihood of a fundamental repricing.
What to watch
The filing does not state tax, diversification, or personal liquidity drivers; without those details, the signal should be discounted versus fundamental catalysts.
Background
This is an SEC Form 4 insider transaction disclosure for Incyte, reported via SEC EDGAR.
Ticker impact
Incyte Form 4 shows EVP and Chief Scientific Officer Mayes Patrick A sold about 47,954 shares for roughly $5.73M under a 10b5-1 plan.
Likely minimal near-term price impact; any reaction is more sentiment-driven than fundamental.
The article discloses only an open-market sale by an insider, explicitly under a pre-arranged 10b5-1 plan, with no accompanying guidance, deal, or regulatory event.
Market effects
No sector-wide read-through is provided beyond a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
A 10b5-1 sale can reflect scheduled liquidity needs rather than bearish expectations, so the market may overreact if it treats it as discretionary selling.
Key entities
- issuerIncyte Corp
Subject of the Form 4 insider sale disclosure.
- insiderMayes Patrick A
EVP and Chief Scientific Officer who sold shares.
